Molecular mitigation: Deleting microRNA-155 reduces autoimmune response

December 24, 2013 by Stuart Mason Dambrot, Medical Xpress feature
Autoantigen-induced GC reactions are reduced in miR-155−/−-Faslpr mice. (A) The frequency of GC B cells within the CD19 gate using PNA-phycoerythrin (PE) and GL-7-FITC. Plots are representative of 5–10 experiments. B6 (n = 5), miR-155−/− (n = 5), miR-155−/−-Faslpr (n = 10), Faslpr (n = 10). (B) The frequency of spleen GC B cells within the CD19 gate was determined from A. Each symbol represents one mouse. (C) The frequency of pLN GC B cells within the CD19 gate was determined from A. (D) The absolute number of spleen GC B cells was calculated from B. P values were determined using the GraphPad Software Student t test. (E) Immunohistochemistry of spleens and pLNs was done using paraffin sections. Arrows indicates germinal centers stained with PNA (brown) and counterstained with hematoxylin. Blue stain indicates follicles. Credit: Copyright © PNAS, doi:10.1073/pnas.1317632110

(Medical Xpress)—While our immune system protects us from myriad bacterial and viral attacks by producing antigen-specific antibodies, this process can sometimes go awry. In such cases, the antibodies target cells and tissues of our own bodies, leading to autoimmunity and a resulting autoimmune disease, examples of which include Type I diabetes, psoriasis and lupus. (Lupus produces antibodies that attack primarily the kidneys.) Recently, scientists at Beth Israel Deaconess Medical Center, Harvard Medical School demonstrated that ablating the regulatory molecule microRNA-155 (also referred to as miR-155), which normally promotes antibody production, prevents harmful antibody production and thereby alleviates lupus-like disease in laboratory mice. The researchers say that their results suggest the possibility of targeting microRNA-155 to treat autoimmune diseases.

Dr. To-Ha Thai discussed the paper that she and her co-authors recently published in Proceedings of the National Academy of Sciences. "MiR-155 regulates systemic autoimmunity in part by controlling the activation threshold of lymphocytes in response to autoantigens," Thai tells Medical Xpress. "In this case, we showed that miR-155 modulates the of SHIP-1, which is a negative regulator of B-cell receptor activation." (A B-cell receptor, or BCR, is a transmembrane protein located on the outer surface of B , which belong to a group of known as lymphocytes.) Specifically, the paper shows that the enzyme SHIP-1 is decreased in B cells from lupus-prone mice, resulting in the hyperactivation of these B cells and, in turn, leading to autoantibody overproduction. Deleting miR-155 in lupus-prone mice reverses this increase almost completely, thus dampening autoantibody production and resulting in the amelioration of lupus-like symptoms – for example, fewer double-stranded DNA (dsDNA) autoantibodies and less kidney damage. (Double-stranded DNA, the double helix form in which DNA occurs in chromosomes, is a molecule of DNA consisting of two parallel strands joined by hydrogen bonds between the complementary aromatic heterocyclic organic compounds purines and pyrimidines.)

"MiR-155 regulates the expression levels of SHIP-1, which is a negative regulator of B- receptor activation," Thai continues. "SHIP-1 dampens BCR activation and, therefore, B-cell activation and antibody production. We think that miR-155 is transiently induced upon B-cell activation to control SHIP-1 expression to allow BCR activation to proceed for a finite time." In an autoimmune environment, Thai explains, autoantigens constantly activate B cells to express miR-155 – and this persistent expression of miR-155 results in the sustained repression of SHIP-1, which will eventually lead to the continuous and prolonged activation of autoreactive B cells and thus autoantibody production.

"We think that miR-155 is a good target to treat for two reasons," Thai notes. "First, it's only induced when cells are activated, and so will only affect the activated cells that are abundant in autoimmune diseases. Second, we and others find that the deletion of miR-155 only affects the production of autoantibodies – not the more protective natural antibodies – so targeting miR-155 may not pose a danger to an individual, since protective remains intact."

Moving forward, Thai says, she will attempt to address the confounding findings that they and other investigators have observed – namely, that miR-155 seems to regulate Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibody responses differentially depending on the type of antigens used. (IgG is the most abundant type of antibody, and is found in all body fluids and protects against bacterial and viral infections. IgM, which is found mainly in the blood and lymph fluid, is the first to be made by the body to fight a new infection.) "More specifically," she adds, "in some studies miR-155 affects both IgG and IgM responses – but in others, it only affects IgG responses. We will continue to further our understanding of this conundrum."

In addition, the researchers will continue to dissect how the is controlled. "We're looking into the role of other epigenetic modifications in the regulation of the adaptive immune response," Thai tells Medical Xpress. "We would also like to work with industries to develop means to target miR-155 for the treatment of autoimmune diseases."

The other areas of research that might benefit from their study, Thai concludes, are vaccines, immunity, and other autoimmune diseases such as rheumatoid arthritis, cancer, and infection.

Explore further: Researchers say one specific microrna promotes tumor growth and cancer spread

More information: Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in the Faslpr mouse, PNAS December 10, 2013 vol. 110no. 50 20194-20199, doi:10.1073/pnas.1317632110

Related Stories

Researchers say one specific microrna promotes tumor growth and cancer spread

April 3, 2013
Researchers at Moffitt Cancer Center have determined that the overexpression of microRNA-155 (miR-155), a short, single strand of ribonucleic acid encoded by the miR-155 host gene, promotes the growth of blood vessels in ...

Study identifies possible new acute leukemia marker, treatment target

May 13, 2013
A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia that has normal-looking chromosomes under the microscope (that is, cytogenetically normal ...

Mini-molecule governs severity of acute graft vs. host disease, study finds

March 12, 2012
Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant.

Atherosclerosis: Specific microRNAs promote inflammation

March 22, 2013
(Medical Xpress)—Atherosclerosis, an inflammatory reaction, is at the root of the most common forms of cardiovascular disease. Researchers at Ludwig-Maximilians-Universitaet in Munich have now identified a microRNA that ...

Newly identified immune receptor may activate B cells in autoimmunity

December 18, 2013
A newly identified immune protein influences each person's response to vaccines and risk for autoimmune diseases like lupus and multiple sclerosis, according to a study published today by researchers from the School of Medicine ...

Recommended for you

Mumps resurgence likely due to waning vaccine-derived immunity

March 21, 2018
A resurgence of mumps in the U.S. among vaccinated young adults appears to be due to waning of vaccine-induced immunity, according to a new analysis from Harvard T.H. Chan School of Public Health. Researchers found that vaccine-derived ...

Western diet depletes artery-protecting immune cells

March 21, 2018
New research from scientists at the La Jolla Institute For Allergy and Immunology shows how a diet high in fat and cholesterol depletes the ranks of artery-protecting immune cells, turning them into promoters of inflammation, ...

Quintupling inhaler medication may not prevent asthma attacks in children

March 19, 2018
Children with mild to moderate asthma do not benefit from a common practice of increasing their inhaled steroids at the first signs of an asthma exacerbation, according to clinical trial results published in The New England ...

How allergens trigger asthma attacks

March 19, 2018
A team of Inserm and CNRS researchers from the Institute of Pharmacology and Structural Biology have identified a protein that acts like a sensor detecting allergens in the respiratory tract that are responsible for asthma ...

Single steroid-bronchodilator treatment for control and rescue improves persistent asthma

March 19, 2018
When it comes to treating teens and adults with persistent asthma, using a single corticosteroid and long-acting bronchodilator treatment for both daily asthma control and for rescue relief during sudden asthma attacks is ...

Obesity and health problems: New research on a safeguard mechanism

March 16, 2018
Obesity and its negative impacts on health - including metabolic syndrome, type-2 diabetes mellitus and cardiovascular complications - are a global pandemic (Taubes, 2009). The worldwide incidence of obesity has more than ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.